充电优化可以提高胆酸盐突变酶抑制剂的效力和选择性
1Laboratorium für Organische Chemie, Swiss Federal Institute of Technology, ETH Hönggerberg, CH-8093 Zürich, Switzerland.
Journal of the American Chemical Society
|May 8, 2003
概括
计算电荷优化改进了可里斯马特突变酶抑制. 修改二碳酸盐抑制剂与基组增强强效和选择性对抗细菌细菌的 chorismate 突变酶 (BsCM).
科学领域:
- 生物化学 生物化学
- 计算化学计算化学
- 酶抑制可以抑制酶.
背景情况:
- 合力酶突变酶是石基胺通路中的关键酶.
- 过渡状态模拟抑制剂是研究酶机制的宝贵工具.
- 计算方法可以指导改进的酶抑制剂的设计.
研究的目的:
- 为了计算优化一个高亲和度的 chorismate 突变酶抑制剂.
- 通过酶抑制试验,通过实验验证计算预测.
- 评估修改对抑制剂强度和选择性的影响.
主要方法:
- 双碳酸盐过渡状态模拟抑制剂的计算电荷优化.
- 一个修改后的抑制剂的合成与一个基组替代.
- 使用Bacillus subtilis chorismate mutase (BsCM) 和Escherichia coli chorismate mutase (EcCM) 的酶抑制测定. 这种测试是指使用Bacillus subtilis chorismate mutase (BsCM) 和Escherichia coli chorismate mutase (EcCM) 进行的酶抑制测定.
- 使用截断的BSCM变体进行实验,以研究C端相互作用.
主要成果:
- 亚替代抑制剂显示出对BsCM的功效增加了3倍.
- 酶切断实验揭示了与抑制剂的有利C端相互作用.
- 酸衍生物对BsCM的选择性比EcCM提高了10倍.
- 实验结果在很大程度上与计算预测一致.
结论:
- 计算电荷优化是设计强效和选择性酶抑制剂的可行策略.
- 该研究强调了酶灵活性和特定氨基酸相互作用在抑制剂结合中的重要性.
- 这种修改后的抑制剂在向胆酸盐突变酶方面取得了重大进展.
相关概念视频
Buffer Effectiveness
Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised.
The buffer capacity is the amount of acid or base that can be added to a given volume...
The buffer capacity is the amount of acid or base that can be added to a given volume...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...


